Form 4: Caris Life Sciences Exec Sells Shares

Brian J. Brille, Vice Chairman and Executive Vice President of Caris Life Sciences, Inc., reported a transaction involving the sale of common stock.

Summary

• Brian J. Brille, Vice Chairman and Executive Vice President of Caris Life Sciences, Inc., engaged in a transaction on May 15, 2026.
• He disposed of 13,987 shares of common stock at a price of $15.25 per share.
• These shares were withheld for the payment of taxes related to the vesting and settlement of Restricted Stock Units (RSUs).
• Following this transaction, Brille beneficially owns 230,303 shares of common stock directly.
• Additionally, he beneficially owns 500,000 shares indirectly through a family trust, into which shares from multiple family trusts were consolidated.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the reported transaction is a standard tax withholding event related to RSU vesting and does not inherently signal a change in the executive's long-term view of the company.

Positives

• The transaction involved shares withheld for tax payments, a common occurrence upon RSU vesting.
• The reporting person retains significant indirect beneficial ownership through a family trust (500,000 shares).

Negatives

• A disposition of 13,987 shares of common stock occurred.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the holdings and activities of company executives and directors. This specific filing details a common event related to equity compensation (RSU vesting and tax settlement).

Stakeholder Impact

• Shareholders: Increased transparency into insider holdings and transactions. The sale is for tax purposes, not necessarily a reflection of negative sentiment.
• Employees: Highlights the mechanics of RSU vesting and tax implications for equity compensation.
• Management: Standard reporting requirement for executive compensation and ownership.

Key Dates

Keywords

Form 4, SEC Filing, Insider Transaction, Caris Life Sciences, Common Stock, RSU Vesting, Tax Withholding, Beneficial Ownership, Brian J. Brille